Publications by authors named "Cristina Astrid Tentori"
Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and Microsimulation.
Caterina Gregorio
,
Marta Spreafico
,
Saverio D'Amico
,
Elisabetta Sauta
,
Gianluca Asti
,
Cristina Astrid Tentori
JCO Clin Cancer Inform
May 2024
Purpose: Decision about the optimal timing of a treatment procedure in patients with hematologic neoplasms is critical, especially for cellular therapies (most including allogeneic hematopoietic stem-cell transplantation [HSCT]). In the absence of evidence from randomized trials, real-world observational data become beneficial to study the effect of the treatment timing. In this study, a framework to estimate the expected outcome after an intervention in a time-to-event scenario is developed, with the aim of optimizing the timing in a personalized manner.
View Article and Find Full Text PDFArticle Synopsis
- Allogeneic hematopoietic stem-cell transplantation is the only curative option for patients with myelodysplastic syndromes, and the timing of this treatment is crucial for maximizing benefits and minimizing risks.
- A decision support system was developed to identify the optimal timing for HSCT based on clinical and genomic data from a large study of over 7,000 patients, comparing outcomes using the Molecular International Prognostic Scoring System (IPSS-M) against traditional scoring methods.
- The findings suggest that patients with lower risk can benefit from delaying transplantation, while those at higher risk should undergo it immediately, indicating that the IPSS-M strategy significantly improves life expectancy and supports personalized treatment plans.
Article Synopsis
- Myelodysplastic syndromes (MDS) require a specialized treatment approach, and the new Molecular International Prognostic Scoring System (IPSS-M) aims to enhance predictions for patient outcomes compared to the older IPSS-R model.
- A study of 2,876 patients revealed that IPSS-M significantly improved survival predictions and shifted risk classifications in nearly half of the patients, even those without detectable gene mutations.
- The findings suggest IPSS-M could better identify patients suitable for hematopoietic stem cell transplantation, although its effectiveness in certain treatment responses remains limited; further research on other influencing factors is necessary.